How AI Is Helping The Fight Against Parkinson’s w/ Gene Mack, CEO, Gain Therapeutics

Episode notes

Send us Fan Mail For decades, Parkinson's patients have been offered only symptom management. No drug has ever slowed the disease itself. A small clinical stage biotech may be about to change that. Gene Mack, CEO, Gain Therapeutics joins host David E. Williams to discuss the science behind a potential first disease modifying therapy for Parkinson's, how AI is accelerating drug discovery, and what it takes to build a biotech in one of the toughest capital markets in years. ️️ABOUT GENE MACK Gene Mack serves as Chief Executive Officer and President of Gain Therapeutics. He joined the Company in April 2024 and brings 25 years of experience in the life sciences sector spanning clinical research, financing and capital markets, investing, corporate strategy and business development. Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023. Previous to Imcyse, Gene was CFO at OncoC4, a privately held biotechnology company that spun out of Merck & Co’s (MSD) $475 million acquisition of OncoImmune in 2020 where he had also been CFO.

• GLP-1s May Reduce Cancer Progression16 / 100
• The Business & Science Behind the GLP-1 Boom44 / 100
• Why We Can Never Have Enough Doctors40 / 100
• The Future of Medicine Is Already Here w/ Bertalan Mesko, The Medical Futurist Institute
• Why Insulin Never Reaches the Liver